ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Eugene Kim Every time Eugene publishes a story, you’ll get an alert straight to your inbox!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--METiS Therapeutics debuts today with $86 million Series A financing to harness artificial intelligence (AI) and machine learning to redefine drug discovery and ...

Metis Solutions will continue to help the Department of Defense and law enforcement agencies analyze threat finance intelligence under a potential five-year, $150M task order from the DoD deputy ...

Backed by cross‑sector research and field feedback, the company Metis today unveils Skyperion Lightweight, a new RF‑based detection product for aerospace and security operators focused on drone ...